Athersys

dult-derived “off-the-shelf” stem cell product platform, for multiple disease indications in the areas of neurological, cardiovascular disease, inflammatory and immune disease, as well as other areas.We have currently six clinical stage programs – including a Phase 2 study in ischemic stroke, a Phase 2 clinical study for the treatment of damage from acute myocardial infarction, a exploratory clinical study in Acute Respiratory Distress Syndrome, and several others. We also have a portfolio of preclinical programs that we are advancing toward clinical stage development. Athersys has forged a network of strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research and clinical institutions, in the United States, Japan and Europe to further develop its platform and products.